<DOC>
	<DOCNO>NCT01927419</DOCNO>
	<brief_summary>The primary purpose study compare objective response rate , determine investigator , Nivolumab combine Ipilimumab versus Ipilimumab monotherapy patient untreated , unresectable , metastatic melanoma</brief_summary>
	<brief_title>Study Nivolumab ( BMS-936558 ) Plus Ipilimumab Compared With Ipilimumab Alone Treatment Previously Untreated , Unresectable , Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Key Eastern Cooperative Oncology Group performance status 0 1 Histologically confirm unresectable Stage III Stage IV melanoma No prior systemic anticancer therapy unresectable metastatic melanoma . Note prior adjuvant neoadjuvant melanoma therapy permit complete least 6 week prior date first dose , related adverse event either return baseline stabilize Tumor tissue obtain metastatic setting unresectable site must provide biomarker analyse sent central laboratory . Biopsy excisional , incisional punch , core needle . Fine needle aspirate cytology sample insufficient Known BRAF V600 mutation status determine FDAapproved test . Patients either V600 wildtype V600 mutationpositive melanoma eligible . Key Active brain metastasis leptomeningeal metastasis . Patients treat brain metastasis eligible evidence progression magnetic resonance image scan least 8 week completion treatment within 28 day prior first dose study drug administration . There must also requirement high dos systemic corticosteroid could result immunosuppression ( &gt; 10 mg/day prednisone equivalent ) least 2 week prior study drug administration Ocular melanoma Patients active , know , suspect autoimmune disease . Those vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>